Mark Hilliard’s Post

View profile for Mark Hilliard, graphic

Principal Scientist, MSAT, Pfizer. 🧬🔬⚗️🧫💊 ⌬

Evan Williams is Professor of Chemistry at UC Berkeley give another prospective on the current and future state of play woth charge detection mass spectrometry (CDMS) 🎯 Summary: Quoting the authors on current issues "Another significant issue is the speed of the devices. A lot of the data being published involves long accumulation times – sometimes an hour or two just to get a decent ion count. That’s acceptable when you’re developing a new technique, but in practical applications, it’s not something most users are willing to endure. Our goal is to reduce this time to be more in line with an LC time scale" Authors vvies on advantage of CDMS to the biopharma industry "The advantage of CD-MS for large particles is similar to the advantage of conventional mass spectrometry for smaller molecules (below a MDa): it provides very accurate mass measurements, quickly, with high sensitivity and specificity. This is valuable for characterizing anything involving large particles, whether it’s viral particles, synthetic lipid nanoparticles, or other examples we’ve been working on. For instance, we can determine how much RNA is in lipid nanoparticles, what the average size of the particles is, and how they are affected by processes like freezing" #massspectrometry #massspec #chemistry #biopharmaceutical #pharma #biotherapeutics #mrna

CD-MS: “A Whole New Ballpark for Mass Spectrometry”

CD-MS: “A Whole New Ballpark for Mass Spectrometry”

theanalyticalscientist.com

To view or add a comment, sign in

Explore topics